254 research outputs found
Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms
Rinitis al·lèrgica; Costos; MedicamentsRinitis alérgica; Costos; MedicamentosAllergic rhinitis; Costs; MedicationsBackground
The practice of allergology varies widely between countries, and the costs and sales for the treatment of rhinitis differ depending on practices and health systems. To understand these differences and their implications, the rhinitis market was studied in some of the EU countries.
Methods
We conducted a pharmaco-epidemiological database analysis to assess the medications that were being prescribed for allergic rhinitis in the years 2016, 2017 and 2018. We used the IQVIA platforms for prescribed medicines (MIDAS®—Meaningful Integration of Data, Analytics and Services) and for OTC medicines (OTC International Market Tracking—OTCims). We selected the five most important markets in the EU (France, Germany, Italy, Poland and Spain).
Results
Intranasal decongestants were excluded from the analyses because they are rarely prescribed for allergic rhinitis. For both Standard Units (SU) and costs, France is leading the other countries. In terms of SU, the four other countries are similar. For costs, Poland is lower than the three others. However, medication use differs largely. For 2018, in SU, intranasal corticosteroid is the first treatment in Poland (70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%), whereas the Italian market is dominated by systemic antihistamines (41.4%) followed by intranasal corticosteroids (30.1%). Results of other years were similar.
Discussion
There are major differences between countries in terms of rhinoconjunctivitis medication usage
ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
Rinitis al·lèrgica; Asma; ImmunoteràpiaRinitis alérgica; Asma; InmunoterapiaAllergic rhinitis; Asthma; ImmunotherapyARIA, Grant/Award Number: N/
A common language to assess allergic rhinitis control : results from a survey conducted during EAACI 2013 Congress
Peer reviewedPublisher PD
Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective : pan European patient survey
Funding for this research was provided by Mylan Inc. Acknowledgements We thank Dr Ruth B Murray (Medscript NZ Ltd) for assistance in drafting and editing this manuscript.Peer reviewedPublisher PD
Systemic Corticosteroids in Asthma : A Call to Action From World Allergy Organization and Respiratory Effectiveness Group
Acknowledgments This manuscript was endorsed by the World Allergy Organization and the Respiratory Effectiveness Group. Editorial support was funded by AstraZeneca and was provided by Katherine Hardy, PhD of Helios Medical Communications, Oxford, Oxfordshire, UK Funding This manuscript was funded by a grant from AstraZeneca. The authors retained full control. AstraZeneca provided a review for scientific accuracy and did not participate in the content development.Peer reviewedPublisher PD
Oral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma
Peer reviewedPostprin
Asthma phenotyping in primary care : applying the International Severe Asthma Registry eosinophil phenotype algorithm across all asthma severities.
Funding: The OPCRD is established and maintained by Optimum Patient Care (OPC) Ltd. This study was funded by AstraZeneca and conducted collaboratively with the OPRI Pte Ltd and OPC Global Ltd. Acknowledgements We thank James Zangrilli, MD, and the entire ISAR Steering Committee for their valued contribution to the design of the study and interpretation of findingsPeer reviewedPublisher PD
Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis
Acknowledgements This study was funded by MedaPharma.Peer reviewedPublisher PD
- …